I play small pharma stocks hoping to get modest profits. Generally the volatility is based on expectations and in Jan if you did an options play on CSLN you won if you closed it. Now with the bad news on Phase III for liver, the stock will probably be a loser for those who did Feb options, but if you look at the technical strength of CSLN and their cash position there may be a surprise coming this spring.
I think that the heat/medicine patented treatment will probably work for some other cancer and trials now underway will be positive enough to make CSLN a very cheap risk play which could result in huge profits for the risk takers.
This news story has 1 comment:
I think that the heat/medicine patented treatment will probably work for some other cancer and trials now underway will be positive enough to make CSLN a very cheap risk play which could result in huge profits for the risk takers.